Fresenius Kabi’s EU Biosimilars ‘Lagging Behind Expectations’

COVID-19 Has Hit Impacted Market

 
• By Dean Rudge
Fresenius Kabi
Fresenius felt the impact of COVID-19 on its biosimilars business in Q2 • Source: Shutterstock

More from Earnings

More from Business